Society of Clinical Research Associates-Food and Drug Administration: Food and Drug Administration Clinical Trial Requirements, Regulations, Compliance, and Good Clinical Practice; Public Workshop, 55728-55729 [2013-22115]
Download as PDF
55728
Federal Register / Vol. 78, No. 176 / Wednesday, September 11, 2013 / Notices
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3520). The collections
of information in §§ 571.1 and 571.6
have been approved under 0910–0546.
IV. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
V. Electronic Access
Persons with access to the Internet
may obtain the draft guidance at either
https://www.fda.gov/AnimalVeterinary/
GuidanceComplianceEnforcement/
GuidanceforIndustry/default.htm or
https://www.regulations.gov.
Dated: September 4, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–22012 Filed 9–10–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0001]
Society of Clinical Research
Associates-Food and Drug
Administration: Food and Drug
Administration Clinical Trial
Requirements, Regulations,
Compliance, and Good Clinical
Practice; Public Workshop
AGENCY:
Food and Drug Administration,
HHS.
emcdonald on DSK67QTVN1PROD with NOTICES
ACTION:
Notice of public workshop.
The Food and Drug Administration
(FDA) is announcing the following
public workshop entitled ‘‘Educational
Conference Co-Sponsored With the
Society of Clinical Research Associates
(SoCRA).’’ The public workshop
regarding FDA’s clinical trial
requirements is designed to aid the
clinical research professional’s
understanding of the mission,
responsibilities, and authority of FDA,
and to facilitate interaction with FDA
representatives. The program will focus
on the relationships among FDA and
clinical trial staff, investigators, and
institutional review boards (IRBs).
VerDate Mar<15>2010
16:50 Sep 10, 2013
Jkt 229001
Individual FDA representatives will
discuss the informed consent process
including the informed consent
documents; regulations relating to
drugs, devices, and biologics; as well as
inspections of clinical investigators, of
IRBs, and of research sponsors.
Date and Time: The public workshop
will be held on November 6 and 7, 2013,
from 8 a.m. to 5 p.m.
Location: The public workshop will
be held at the JW Marriott Atlanta
Buckhead Hotel, 3300 Lenox Rd. NE.,
Atlanta, GA 30326, 404–262–3344.
Attendees are responsible for their
own accommodations. Please mention
SoCRA to receive the hotel room rate of
$185.00 plus applicable taxes (available
until October 15, 2013, or until the
SoCRA room block is filled).
Contact Person: JoAnn Pittman, Food
and Drug Administration, 60 Eighth
Street NE., Atlanta, GA 30309,
voicemail: 404–253–1272, FAX: 404–
253–1202, or Society of Clinical
Research Associates (SoCRA), 530 West
Butler Ave., Suite 109, Chalfont, PA
18914, 800–762–7292 or 215–822–8644,
FAX: 215–822–8633, email:
SoCRAmail@aol.com, Web site:
www.socra.org.
Registration: The registration fee will
cover actual expenses including
refreshments, lunch, materials, and
speaker expenses. Seats are limited;
please submit your registration as soon
as possible. Workshop space will be
filled in order of receipt of registration.
Those accepted into the workshop will
receive confirmation. The cost of the
registration is as follows:
1 Credit(s)TM. Physicians should claim
only the credit commensurate with the
extent of their participation. Continuing
Medical Education for physicians:
SoCRA is accredited by the
Accreditation Council for Continuing
Medical Education to provide
continuing medical education for
physicians. CNE for nurses: SoCRA is an
approved provider of CNE by the
Pennsylvania State Nurses Association
(PSNA), an accredited approver by the
American Nurses Credentialing Center’s
Commission on Accreditation (ANCC).
ANCC/PSNA Provider Reference
Number: 205–3–A–09.
Registration instructions: To register,
please submit a registration form with
your name, affiliation, mailing address,
telephone, fax number, and email, along
with a check or money order payable to
‘‘SoCRA’’. Mail to: Society of Clinical
Research Associates (SoCRA), 530 West
Butler Ave., Suite 109, Chalfont, PA
18914.
To register via the Internet, go to:
https://www.socra.org/html/FDA_
Conference.htm. (FDA has verified the
Web site addresses throughout this
document, but we are not responsible
for any subsequent changes to the Web
sites after this document is published in
the Federal Register).
Payment by major credit card is
accepted (Visa/MasterCard/AMEX
only). For more information on the
meeting registration, or for questions on
the public workshop, contact SoCRA,
800–762–7292 or 215–822–8644, FAX:
215–822–8633, or email: SoCRAmail@
aol.com.
SoCRA member ........
SoCRA nonmember
(includes membership).
Federal Government
SoCRA member.
Federal Government
SoCRA nonmember.
FDA Employee ..........
SUPPLEMENTARY INFORMATION:
$575.00.
$650.00.
$450.00.
$525.00.
(Free) Fee Waived.
If you need special accommodations
due to a disability, please contact
SoCRA, 800–762–7292 or 215–822–
8644, FAX: 215–822–8633, or email:
SoCRAmail@aol.com at least 21 days in
advance.
Extended periods of question and
answer and discussion have been
included in the program schedule.
SoCRA designates this education
activity for a maximum of 13.3
Continuing Education (CE) credits for
SoCRA CE and continuing nurse
education (CNE). SoCRA designates this
live activity for a maximum of 13.3
American Medical Association
Physicians Recognition Award Category
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
The
public workshop helps fulfill the
Department of Health and Human
Services’ and FDA’s important mission
to protect the public health. The public
workshop will provide those engaged in
FDA-regulated (human) clinical trials
with information on a number of topics
concerning FDA requirements related to
informed consent, clinical investigation
requirements, IRB inspections,
electronic record requirements, and
investigator initiated research. Topics
for discussion include the following: (1)
The Role of the FDA District Office
Relative to the Bioresearch Monitoring
Program (BIMO); (2) Modernizing FDA’s
Clinical Trials/BIMO Programs; (3)
What FDA Expects in a Pharmaceutical
Clinical Trial; (4) Medical Device
Aspects of Clinical Research; (5)
Adverse Event Reporting—Science,
Regulation, Error, and Safety; (6)
Working with FDA’s Center for
Biologics Evaluation and Research; (7)
Ethical Issues in Subject Enrollment; (8)
Keeping Informed and Working
E:\FR\FM\11SEN1.SGM
11SEN1
Federal Register / Vol. 78, No. 176 / Wednesday, September 11, 2013 / Notices
Together; (9) FDA Conduct of Clinical
Investigator Inspections; (10)
Investigator Initiated Research; (11)
Meetings with FDA—Why, When, and
How; (12) Part 11 Compliance—
Electronic Signatures; (13) IRB
Regulations and FDA Inspections; (14)
Informed Consent Regulations; (15) The
Inspection is Over—What Happens
Next? Possible FDA Compliance
Actions; and (16) Question and Answer
Session/Panel Discussion.
FDA has made education of the drug
and device manufacturing community a
high priority to help ensure the safety
and effectiveness of FDA-regulated
drugs and devices. The public workshop
helps to achieve objectives set forth in
section 406 of the FDA Modernization
Act of 1997 (21 U.S.C. 393) which
includes working closely with
stakeholders and maximizing the
availability and clarity of information to
stakeholders and the public. The public
workshop also is consistent with the
Small Business Regulatory Enforcement
Fairness Act of 1996 (Public Law 104–
121), as outreach activities by
Government Agencies to small
businesses.
Dated: September 6, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–22115 Filed 9–10–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Proposed Collection: Public
Comment Request
Health Resources and Services
Administration, HHS.
ACTION: Notice.
AGENCY:
In compliance with the
requirement for opportunity for public
comment on proposed data collection
projects (Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995), the
Health Resources and Services
Administration (HRSA) announces
plans to submit an Information
Collection Request (ICR), described
below, to the Office of Management and
Budget (OMB). Prior to submitting the
ICR to OMB, HRSA seeks comments
from the public regarding the burden
emcdonald on DSK67QTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:50 Sep 10, 2013
Jkt 229001
estimate below, or any other aspect of
the ICR.
DATES: Comments on this Information
Collection Request must be received
within 60 days of this notice.
ADDRESSES: Submit your comments to
paperwork@hrsa.gov or mail the HRSA
Information Collection Clearance
Officer, Room 10–29, Parklawn
Building, 5600 Fishers Lane, Rockville,
MD 20857.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and draft
instruments, email paperwork@hrsa.gov
or call the HRSA Information Collection
Clearance Officer at (301) 443–1984.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the
information request collection title for
reference.
Information Collection Request Title:
Uniform Project Description and
Application Guide—SF 424 NonConstruction.
OMB No. 0915-xxxx—New.
Abstract: The Health Resources and
Services Administration is requesting
clearance for the Uniform Project
Description (UPD) and Application
Guide to be used in conjunction with
the SF–424 Non-Construction
application kit by program offices to
solicit application information for grants
and cooperative agreements.
Need and Proposed Use of the
Information: The HRSA SF–424
Application Guide provides detailed
standard instructions to help applicants
prepare and submit applications
electronically to HRSA through
Grants.gov. The Guide is used in
conjunction with the HRSA UPD that
provides a menu of narratives from
which the program office can select for
inclusion within a program-specific
grant or cooperative agreement funding
opportunity announcement (FOA). UPD
text options selected for use in a given
FOA define the required project
description portion to the applicant.
The ability to pick and choose standard
language that is appropriate for any
given FOA reduces the burden
associated with application preparation
by eliminating irrelevant portions of the
application for a given announcement.
In addition, it provides consistency in
the application review process.
Much of the information required in
applications for project grants and
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
55729
cooperative agreements is required by
HHS Uniform Administrative
Requirements for Grants and
Cooperative Agreements at the
following citations: 45 CFR part 74, 45
CFR part 92, applicable program
regulations in 42 CFR chapters I and IV,
and applicable administrative
regulations in 45 CFR subtitle A.
HRSA program offices, grants
management officials, and expert nonfederal and federal panel reviewers use
the collected information provided
through grant applications to select and
award discretionary grants. Program
offices use the information to ensure
that the authorizing legislation and
applicable program regulations will be
implemented through any funded
project, and that applicant entities are
eligible to receive HRSA funds. Expert
non-federal and federal objective review
panelists score the information provided
in applications as they evaluate
applications in the context of the FOA’s
published criteria to ensure that the best
proposed projects are recommended for
funding. Grants management officials
use the information to ensure
appropriate federal stewardship of
federal grant funds and that proposed
budgeted project costs are allowable,
allocable, and reasonable.
Likely Respondents: Eligible
organizations may include state, local,
and Indian Tribal governments;
institutions of higher education; other
non-profit organizations (including
faith-based, community-based, and
Tribal organizations); and hospitals. In
limited cases, foreign organizations may
apply.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this Information
Collection Request are summarized in
the table below.
E:\FR\FM\11SEN1.SGM
11SEN1
Agencies
[Federal Register Volume 78, Number 176 (Wednesday, September 11, 2013)]
[Notices]
[Pages 55728-55729]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-22115]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-0001]
Society of Clinical Research Associates-Food and Drug
Administration: Food and Drug Administration Clinical Trial
Requirements, Regulations, Compliance, and Good Clinical Practice;
Public Workshop
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public workshop.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing the following
public workshop entitled ``Educational Conference Co-Sponsored With the
Society of Clinical Research Associates (SoCRA).'' The public workshop
regarding FDA's clinical trial requirements is designed to aid the
clinical research professional's understanding of the mission,
responsibilities, and authority of FDA, and to facilitate interaction
with FDA representatives. The program will focus on the relationships
among FDA and clinical trial staff, investigators, and institutional
review boards (IRBs). Individual FDA representatives will discuss the
informed consent process including the informed consent documents;
regulations relating to drugs, devices, and biologics; as well as
inspections of clinical investigators, of IRBs, and of research
sponsors.
Date and Time: The public workshop will be held on November 6 and
7, 2013, from 8 a.m. to 5 p.m.
Location: The public workshop will be held at the JW Marriott
Atlanta Buckhead Hotel, 3300 Lenox Rd. NE., Atlanta, GA 30326, 404-262-
3344.
Attendees are responsible for their own accommodations. Please
mention SoCRA to receive the hotel room rate of $185.00 plus applicable
taxes (available until October 15, 2013, or until the SoCRA room block
is filled).
Contact Person: JoAnn Pittman, Food and Drug Administration, 60
Eighth Street NE., Atlanta, GA 30309, voicemail: 404-253-1272, FAX:
404-253-1202, or Society of Clinical Research Associates (SoCRA), 530
West Butler Ave., Suite 109, Chalfont, PA 18914, 800-762-7292 or 215-
822-8644, FAX: 215-822-8633, email: SoCRAmail@aol.com, Web site:
www.socra.org.
Registration: The registration fee will cover actual expenses
including refreshments, lunch, materials, and speaker expenses. Seats
are limited; please submit your registration as soon as possible.
Workshop space will be filled in order of receipt of registration.
Those accepted into the workshop will receive confirmation. The cost of
the registration is as follows:
------------------------------------------------------------------------
------------------------------------------------------------------------
SoCRA member.............................. $575.00.
SoCRA nonmember (includes membership)..... $650.00.
Federal Government SoCRA member........... $450.00.
Federal Government SoCRA nonmember........ $525.00.
FDA Employee.............................. (Free) Fee Waived.
------------------------------------------------------------------------
If you need special accommodations due to a disability, please
contact SoCRA, 800-762-7292 or 215-822-8644, FAX: 215-822-8633, or
email: SoCRAmail@aol.com at least 21 days in advance.
Extended periods of question and answer and discussion have been
included in the program schedule. SoCRA designates this education
activity for a maximum of 13.3 Continuing Education (CE) credits for
SoCRA CE and continuing nurse education (CNE). SoCRA designates this
live activity for a maximum of 13.3 American Medical Association
Physicians Recognition Award Category 1 Credit(s)TM.
Physicians should claim only the credit commensurate with the extent of
their participation. Continuing Medical Education for physicians: SoCRA
is accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians. CNE
for nurses: SoCRA is an approved provider of CNE by the Pennsylvania
State Nurses Association (PSNA), an accredited approver by the American
Nurses Credentialing Center's Commission on Accreditation (ANCC). ANCC/
PSNA Provider Reference Number: 205-3-A-09.
Registration instructions: To register, please submit a
registration form with your name, affiliation, mailing address,
telephone, fax number, and email, along with a check or money order
payable to ``SoCRA''. Mail to: Society of Clinical Research Associates
(SoCRA), 530 West Butler Ave., Suite 109, Chalfont, PA 18914.
To register via the Internet, go to: https://www.socra.org/html/FDA_Conference.htm. (FDA has verified the Web site addresses
throughout this document, but we are not responsible for any subsequent
changes to the Web sites after this document is published in the
Federal Register).
Payment by major credit card is accepted (Visa/MasterCard/AMEX
only). For more information on the meeting registration, or for
questions on the public workshop, contact SoCRA, 800-762-7292 or 215-
822-8644, FAX: 215-822-8633, or email: SoCRAmail@aol.com.
SUPPLEMENTARY INFORMATION: The public workshop helps fulfill the
Department of Health and Human Services' and FDA's important mission to
protect the public health. The public workshop will provide those
engaged in FDA-regulated (human) clinical trials with information on a
number of topics concerning FDA requirements related to informed
consent, clinical investigation requirements, IRB inspections,
electronic record requirements, and investigator initiated research.
Topics for discussion include the following: (1) The Role of the FDA
District Office Relative to the Bioresearch Monitoring Program (BIMO);
(2) Modernizing FDA's Clinical Trials/BIMO Programs; (3) What FDA
Expects in a Pharmaceutical Clinical Trial; (4) Medical Device Aspects
of Clinical Research; (5) Adverse Event Reporting--Science, Regulation,
Error, and Safety; (6) Working with FDA's Center for Biologics
Evaluation and Research; (7) Ethical Issues in Subject Enrollment; (8)
Keeping Informed and Working
[[Page 55729]]
Together; (9) FDA Conduct of Clinical Investigator Inspections; (10)
Investigator Initiated Research; (11) Meetings with FDA--Why, When, and
How; (12) Part 11 Compliance--Electronic Signatures; (13) IRB
Regulations and FDA Inspections; (14) Informed Consent Regulations;
(15) The Inspection is Over--What Happens Next? Possible FDA Compliance
Actions; and (16) Question and Answer Session/Panel Discussion.
FDA has made education of the drug and device manufacturing
community a high priority to help ensure the safety and effectiveness
of FDA-regulated drugs and devices. The public workshop helps to
achieve objectives set forth in section 406 of the FDA Modernization
Act of 1997 (21 U.S.C. 393) which includes working closely with
stakeholders and maximizing the availability and clarity of information
to stakeholders and the public. The public workshop also is consistent
with the Small Business Regulatory Enforcement Fairness Act of 1996
(Public Law 104-121), as outreach activities by Government Agencies to
small businesses.
Dated: September 6, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-22115 Filed 9-10-13; 8:45 am]
BILLING CODE 4160-01-P